Shares of Vertex Pharmaceuticals VRTX decreased 1.4% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 114.63% over the past year to $2.64, which beat the estimate of $2.32.
Revenue of $1,538,000,000 higher by 61.92% year over year, which beat the estimate of $1,470,000,000.
Guidance
Vertex Pharmaceuticals hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $6,000,000,000 and $6,200,000,000.
How To Listen To The Conference Call
Date: Oct 29, 2020
Time: 04:30 PM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1392359&tp_key=78b8fb16aa
Recent Stock Performance
Company's 52-week high was at $306.08
52-week low: $192.32
Price action over last quarter: down 23.89%
Company Description
Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
